IBDEI025 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,453,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,453,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,454,0)
 ;;=C82.30^^2^21^28
 ;;^UTILITY(U,$J,358.3,454,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,454,1,3,0)
 ;;=3^Follicular lymphoma grade IIIa, unspecified site
 ;;^UTILITY(U,$J,358.3,454,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,454,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,455,0)
 ;;=C82.29^^2^21^20
 ;;^UTILITY(U,$J,358.3,455,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,455,1,3,0)
 ;;=3^Foliclar lymph grade III, unsp, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,455,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,455,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,456,0)
 ;;=C82.20^^2^21^27
 ;;^UTILITY(U,$J,358.3,456,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,456,1,3,0)
 ;;=3^Follicular lymphoma grade III, unspecified, unspecified site
 ;;^UTILITY(U,$J,358.3,456,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,456,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,457,0)
 ;;=C82.09^^2^21^23
 ;;^UTILITY(U,$J,358.3,457,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,457,1,3,0)
 ;;=3^Follicular lymphoma grade I, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,457,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,457,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,458,0)
 ;;=C82.10^^2^21^26
 ;;^UTILITY(U,$J,358.3,458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,458,1,3,0)
 ;;=3^Follicular lymphoma grade II, unspecified site
 ;;^UTILITY(U,$J,358.3,458,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,458,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,459,0)
 ;;=C82.00^^2^21^24
 ;;^UTILITY(U,$J,358.3,459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,459,1,3,0)
 ;;=3^Follicular lymphoma grade I, unspecified site
 ;;^UTILITY(U,$J,358.3,459,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,459,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,460,0)
 ;;=C82.90^^2^21^31
 ;;^UTILITY(U,$J,358.3,460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,460,1,3,0)
 ;;=3^Follicular lymphoma, unspecified, unspecified site
 ;;^UTILITY(U,$J,358.3,460,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,460,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,461,0)
 ;;=C82.99^^2^21^30
 ;;^UTILITY(U,$J,358.3,461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,461,1,3,0)
 ;;=3^Follicular lymphoma, unsp, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,461,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,461,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,462,0)
 ;;=C84.00^^2^21^53
 ;;^UTILITY(U,$J,358.3,462,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,462,1,3,0)
 ;;=3^Mycosis fungoides, unspecified site
 ;;^UTILITY(U,$J,358.3,462,1,4,0)
 ;;=4^C84.00
 ;;^UTILITY(U,$J,358.3,462,2)
 ;;=^5001621
 ;;^UTILITY(U,$J,358.3,463,0)
 ;;=C84.09^^2^21^52
 ;;^UTILITY(U,$J,358.3,463,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,463,1,3,0)
 ;;=3^Mycosis fungoides, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,463,1,4,0)
 ;;=4^C84.09
 ;;^UTILITY(U,$J,358.3,463,2)
 ;;=^5001630
 ;;^UTILITY(U,$J,358.3,464,0)
 ;;=C84.60^^2^21^8
 ;;^UTILITY(U,$J,358.3,464,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,464,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-positive, unsp site
 ;;^UTILITY(U,$J,358.3,464,1,4,0)
 ;;=4^C84.60
 ;;^UTILITY(U,$J,358.3,464,2)
 ;;=^5001651
 ;;^UTILITY(U,$J,358.3,465,0)
 ;;=C84.69^^2^21^10
 ;;^UTILITY(U,$J,358.3,465,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,465,1,3,0)
 ;;=3^Anaplstc lg cell lymph, ALK-pos, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,465,1,4,0)
 ;;=4^C84.69
 ;;^UTILITY(U,$J,358.3,465,2)
 ;;=^5001660
 ;;^UTILITY(U,$J,358.3,466,0)
 ;;=C84.70^^2^21^7
 ;;^UTILITY(U,$J,358.3,466,1,0)
 ;;=^358.31IA^4^2
 ;;
 ;;$END ROU IBDEI025
